IDT Biologika Announces Plans Viral Vaccine Production Buildout, Expands Workforce

IDT Biologika Announces Plans Viral Vaccine Production Buildout, Expands Workforce

IDT Biologika Introduces Plans to Expand Vaccine Capacity and Announces Workforce Expansion

Capabilities to Be Highlighted at CPhI/ICSE 2010

Dessau-Rosslau, Germany and Herndon , Va. , U.S. - 20 September 2010 - IDT Biologika GmbH, a global integrated contract manufacturer of vaccines and biopharmaceuticals, today introduced plans to expand its viral vaccine production capacity with the addition of a new high-speed filling line and additional lyophilisation capacity. The company also announced the addition of 80 employees to its workforce - an increase of approximately 11 % - to meet growth in demand for its biologics production. IDT Biologika will showcase its integrated production capabilities, from concept through commercialization, at the International Contract Services Exhibition 2010 (ICSE 2010) in Paris , being held from October 5 to October 7, 2010. ICSE 2010 will take place at the Villepinte Paris Nord Convention Centre, in conjunction with the CPhI Worldwide. IDT Biologika representatives - including Sonja Stoyantschova, newly hired Director of Sales & Marketing for Pharmaceuticals - will be available to discuss the company's full suite of manufacturing and packaging capabilities during the exhibition, at Hall 4, Stand 4B28.

Dr. Ralf Pfirmann, CEO of IDT Biologika, said, "We are proud to be one of the few industrial service manufacturers in the world with the capacity and expertise to handle large-scale campaign manufacture of various vaccines and biopharmaceuticals. In light of the resurgence of interest by large pharma in developing new vaccines and the planned expansion of our filling capacity, IDT remains well positioned to provide ongoing best-in-class service to these innovative companies; from the bench through clinical development and commercial production. In addition, as one of the premiere quality outsourcing partners in Europe for global biotech companies - particularly in the complex area of biologics - our recent workforce expansion will accommodate increased demand in this area, and ensure the highest levels of efficiency and quality for our customers."

IDT Biologika expects to expand its extraordinarily flexible, multipurpose vaccine manufacturing facilities via the completion of its new high-speed viral vaccine line by mid-2013. This line will substantially expand fill-finish capacity and well position the company for anticipated growth in demand for this service. The company's existing vaccine facility features two contained manufacturing lines with segregated operations for preparation of cells, virus propagation and virus purification. All IDT Biologika facilities have been inspected by international regulatory agencies such as the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA).

"For the past two decades, we have and continue to invest in state-of-the-art facilities, design and human expertise," continued Mr. Pfirmann. "In addition, beyond our equipment and technical know-how, we believe in taking a collaborative wholeproject approach that allows us to respond to customers' needs in very short timeframes as opposed to working on a turnkey basis. We look forward to seeing current partners and meeting potential new customers at ICSE 2010."

For more information visit IDT Biologika at CPhI/ICSE 2010, October 5-7 (Hall 4, Stand 4B28).

About IDT Biologika IDT Biologika GmbH is an innovative, privately-held company with more than 85 years of experience in researching, developing, manufacturing, and marketing of biologics. The company focuses on three core areas - animal health, human vaccines, and pharmaceuticals: For veterinary markets, IDT Biologika manufactures and markets a comprehensive range of high-quality vaccines and other products for animal health. For vaccines, IDT Biologika offers development services and manufacturing facilities for clinical phase I to III as well as commercial supplies for leading edge viral and bacterial human vaccines, addressing health issues such as tuberculosis, AIDS, malaria and pox. For pharmaceutical markets, IDT Biologika specializes in the development and manufacture of sterile liquid drugs, providing fully-integrated services range from formulation development and clinical manufacturing through large-scale production, packaging and quality control. The company has experience in technically sophisticated projects, such as innovative biopharmaceuticals and lyophilized compounds, in EMA- and FDA-inspected facilities, most of which have been built within the last five years. IDT Biologika is a member of the Klocke Group. With more than 1300 employees at six locations worldwide the Klocke Group has been offering its customers a complete range of services for contract manufacture and contract packaging, from development, production and filling through to the development of customised packaging methods and packing for more than 40 years. The Group also has extensive experience in contract manufacturing of solid dosage forms and cytostatics. For more information about IDT Biologika, visit www.idt-biologika.com.

Suggested Articles

CSL has sued a former exec who its says stole thousands of key documents as he left for competitor Pharming.

Influential U.S. cost watchdog ICER gave its blessing to Johnson & Johnson and Amarin's CV drugs. But there's a big catch for both meds.

Private equity player Ampersand Capital Partners is backing another CDMO, this one targeted at sterile injectables.